Skip to main content
/
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.30
-0.51 (-2.86%)
At close: May 9, 2025, 4:00 PM
17.85
+0.55 (3.18%)
After-hours: May 9, 2025, 7:52 PM EDT

Apellis Pharmaceuticals Revenue by Segment

Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Product
696.78M709.95M657.44M580.05M490.56M366.28M247.28M165.77M
Product Growth
42.04%93.83%165.87%249.90%434.47%462.71%352.49%292.02%
Collaboration License and Other
79.06M71.41M57.78M48.74M33.51M30.31M25.60M18.76M
Collaboration License and Other Growth
135.91%135.62%125.73%159.80%137.61%193.41%-56.17%-65.49%

Product Revenue by Segment

Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Syfovre
604.58M611.85M558.35M481.67M394.39M275.28M160.98M85.70M
Syfovre Growth
53.30%122.26%246.84%462.03%2,048.08%---
Empaveli
92.22M98.13M99.13M98.42M96.21M91.04M86.34M80.14M
Empaveli Growth
-4.15%7.79%14.81%22.81%30.91%39.72%57.93%89.58%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.